Initiator Pharma: Financial calendar for 2023

Regulatory

Initiator Pharma A/S ("Initiator" or the "Company") announces that the board of directors expects to publish financial reports according to the following schedule:

Year-end report 2022 (Q4) 17 February 2023
Interim Q1 2023 report 5 May 2023
Annual General Meeting 2023 26 May 2023
Interim report 1st half 2023 25 August 2023
Interim Q3 2023 report 10 November 2023
Year-end report 2023 (Q4) 23 February 2024

For additional information about Initiator Pharma, please contact:

Claus Elsborg Olesen, CEO
Telephone: +45 6126 0035
E-mail: [email protected]

About Initiator Pharma

Initiator Pharma A/S is a Danish clinical stage life science company developing innovative drugs that target key unmet medical needs within the central and peripheral nervous system. Initiator Pharma’s pipeline consists of three clinical programs – the drug candidates IP2018 and IPED2015 for treatment of erectile dysfunction of psychogenic and organic origin, respectively, and the orphan drug candidate IPTN2021 developed for Trigeminal Neuralgia, a severe neuropathic pain condition. 
 
Initiator Pharma is listed on Nasdaq First North Growth Market (ticker: INIT). Redeye AB is the company’s Certified Adviser. For more information, please visit www.initiatorpharma.com.

Attachments

Initiator Pharma: Financial calendar for 2023

Documents